Accelerator Nordic’s subsidiary, AddBIO has developed a proprietary bioactive nanolayer called Zolidd for dental and orthopedic implants that releases a bone strengthening drug called bisphosphonate.
According to a randomized clinical study performed at Linköping University Hospital in Sweden, bisphosphonate nanolayer has enhanced the stability of dental implants.
AddBIO’s co-founder and a Professor at Linköping University Hospital, Per Aspenberg explained that the improvement of implant stability by local bisphosphonate proves that the time needed to restore normal chewing function can be reduced, which in turn decreases the suffering for the patient.
Zolidd is the first product from a platform technology engineered for the local release of medicines from medical implants, designed by Professors Penti Tengvall and Per Aspenberg from the Linköping University. A nanometer-thick protein layer attached with a bisphosphonate is bonded to a metal implant surface. The release of the bisphosphonate triggers a local effect, which in turn enhances the implant stability.
In the present clinical study, a Zolidd prototype released bisphosphonate in this manner. The study involved 16 patients, each received 2 implants, one without and another with bisphosphonate. Six months later, the implant treated with the bisphosphonate demonstrated enhanced stability in 15 out 16 patients. On X-ray results, the bisphosphonate treated implants already started showing positive effects after two months without any difficulties.
AddBIO’s Chief Executive Officer Dr. Trine Vikinge commented that with these positive results, the company now moves towards the commercialization of Zolidd.
The clinical study results have been reported online in BONE.
Source: http://www.acceleratorab.se